NICE has proposed age-based CA125 thresholds to improve early ovarian cancer detection while reducing unnecessary scans in ...

Ovarian cancer kills an estimated 12,700 women annually, with around 20,000 women getting a diagnosis each year.

Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

Known as "the silent killer" due to its lack of symptoms and reliable screening tests, ovarian cancer remains one of the ...

Ovarian cancer is one of the most common forms of cancer, a type that usually remains undiagnosed for a while in many ...

The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...

Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readiness Company on ...

InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology ...

BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with ...

Age based thresholds for blood tests to detect ovarian cancer should be introduced, the National Institute for Health and ...

University of Manchester researchers have shown that analysis of fluid flushed through a fallopian tube holds promise for ...